Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.

Bailly, Sarah;Cartron, Guillaume;Chaganti, Sridhar;Córdoba, Raul;Visco, Carlo;et.al.
(2022) Hematological Oncology — Vol. 40, n° 4, p. 505-517 (2022)

Files

HematologicalOncology-2022-Bailly-TargetingCD19indiffuselargeBcelllymphomaAnexpertopinionpaper.pdf
  • Open Access
  • Adobe PDF
  • 451.78 KB
Download

Details

Authors
Show more
Abstract
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bailly, S., Cartron, G., Chaganti, S., Córdoba, R., Corradini, P., Düll, J., Ferrarini, I., Osborne, W., Rosenwald, A., Sancho, J.-M., Tilly, H., Van Den Neste, E., Viardot, A., & Visco, C. (2022). Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. Hematological Oncology, 40(4), 505-517. https://doi.org/10.1002/hon.3013 (Original work published 2022)